Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma.

Abstract

Allergic asthma is becoming increasingly prevalent in the developed world, and many common allergens are capable of inducing allergic asthma responses, particularly in atopic individuals. Unmethylated CpG-oligonucleotide (ODN) therapy can shift the immune response to mitigate these allergic responses. Therapeutic and prophylactic delivery of soluble CpG-ODN in preclinical studies has shown promise in treating existing asthma and preventing allergic responses upon subsequent allergen exposure, respectively. However, when CpG-ODN is coupled with nanoparticles or self assembled into nanostructures, improved efficacy of CpG-ODN treatment for several common allergens is observed in preclinical studies and clinical trials. Here we discuss the role of CpG-ODN in treating allergic asthma and how nanoparticle-based delivery can further enhance its therapeutic properties.

• Authors: Brittany E Givens, Sean M Geary, Aliasger K Salem
• Journal: Immunotherapy (Immunotherapy) Vol. 10 Issue 7 Pg. 595-604 (06 2018) ISSN: 1750-7448 [Electronic] England
• PMID: 29569508 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)

Chemical References

• CPG-oligonucleotide
• Cytokines
• Oligodeoxyribonucleotides

Topics

• Animals
• Asthma (genetics, therapy)
• Clinical Trials as Topic
• Cytokines (genetics, metabolism)
• Drug Evaluation, Preclinical
• Humans
• Hypersensitivity (genetics, therapy)
• Hypersensitivity, Immediate
• Nanoparticles (therapeutic use)
• Oligodeoxyribonucleotides (genetics, therapeutic use)
• Th1 Cells (immunology)
• Th2 Cells (immunology)